Portfolio
Selected advisory work across regulatory pathway design, development planning, access strategy, and launch readiness. Client details anonymized.
Top-20 biopharma sponsor
Cross-functional launch governance and medical affairs alignment for a first-in-class intravitreal therapy entering US and EU markets under parallel regulatory review.
12
Markets in first wave
9 mo
Readiness window
6
Workstreams governed
Emerging biotech sponsor
FDA and EMA pathway strategy for a sustained-delivery platform with novel CMC, device interfaces, and clinical endpoints — enabling aligned Phase 2 initiation.
4
Formal agency interactions
2
Protocol iterations pre-Phase 2
Specialty pharma sponsor
Indication prioritization and partnership strategy for a five-asset retinal gene therapy portfolio under capital constraints.
5
Pipeline assets assessed
3
Active partnership tracks
Next steps
Schedule a confidential consultation with our senior advisory team.
